Why did Carl Zeiss Meditec stock drop today?

A Goldman Sachs downgrade to Neutral and a price target cut to €42 weighed on sentiment, pushing the share price down 6.61% to €35.04. The move also reflected ongoing weakness in Q1 expectations and a broader MDAX risk‑off tone, which kept the stock below its key moving averages.

Is the Goldman Sachs downgrade a sell signal?

A downgrade is one data point, not a mandate. It highlights near‑term risks and weaker visibility. We weigh it against fundamentals: solid margins, moderate leverage, and cash generation. The setup likely stays tactical until earnings on 12 February clarify orders, margins, and the path to growth reacceleration.

What are the key technical levels to watch?

Support sits around €34.70–€35 after today’s undercut. On the upside, €38–€39 is the first hurdle, with heavier resistance near €41–€42. The stock trades about 16% below the 50‑day and 28% below the 200‑day, so sustained closes above those levels would improve momentum.

How is valuation after the drop?

The shares trade near 23x TTM earnings and 1.39x sales, with EV/EBITDA around 10x and a dividend yield of roughly 1.69%. That is not distressed, but cheaper than mid‑2024 levels. If growth stabilizes, upside exists. If Q1 disappoints, multiples could compress further.

Global Market Insights

AFX.DE Stock Today: January 21 Goldman Cut Sends Shares to 2017 Lows

ByDanny Kontos January 21, 2026January 21, 2026

Carl Zeiss Meditec stock slumped after a Goldman Sachs downgrade to Neutral and a price target cut to €42, pushing shares to multi‑year lows. The stock AFX.DE last traded at €35.04, down 6.61%, with volume slightly above average. The price now sits about 16% below the 50‑day (€41.71) and 28% under the 200‑day (€48.46). With Q1 flagged as weak and MDAX weakness in focus, investors weigh a 1.69% dividend yield and a 23.2x P/E against sliding momentum ahead of earnings on 12 February 2026.